Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas

References

• Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with malignant endocrine pancreatic tumors. Cancer 1990; 65: 1883–90
   PubMed Web of Science ®Google Scholar
• Öberg K. State of the art and future prospects in the management of neuroendocrine tumor. Q J Nucl Med 2000; 44: 3–12
   PubMedGoogle Scholar
• Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101–7
   PubMed Web of Science ®Google Scholar
• Fjällskog M-L, Sundin A, Westlin J-E, Öberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 2002; 19: 35–42
   PubMed Web of Science ®Google Scholar
• Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: From ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003; 37: 1–19
   PubMed Web of Science ®Google Scholar
• Simon M-P, Pedeutour F, Sirvent N. Deregulation of the platelet-derived growth factor B-chain via fusion with collagen gene COL1A1 in dermatofibrosarcom protuberans and giant-cell fibroblastoma. Nat Genet 1997; 15: 95–8
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342–9
   PubMed Web of Science ®Google Scholar
• Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992; 52: 4550–3
   PubMed Web of Science ®Google Scholar
• Clarke ID, Dirks PB. A human brain tumor-derived PDGFR-alpha deletion mutant is transforming. Oncogene 2003; 22: 722–33
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Sjöblom T, Abramsson A, Ellingsen J, Micke P, Li H, et al. PDGF production by B16 melanoma cells leads to increased coverage of vessels and an associated increase in tumor growth rate. Cancer Res 2004; 64: 2725–33
   PubMed Web of Science ®Google Scholar
• Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929–34
   PubMed Web of Science ®Google Scholar
• Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGFR signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62: 5476–84.
   PubMed Web of Science ®Google Scholar
• Pietras K, Stumm M, Hubert M, Buchdunger E, Rubin K, Heldin CH, et al. STI571 enhances the therapeutic index of epitholone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003; 9: 3779–87
   PubMed Web of Science ®Google Scholar
• Fjällskog M-L, Lejonklou M, Öberg K, Eriksson B, Janson ET. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003; 9: 1469–73
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–45
   PubMed Web of Science ®Google Scholar
• Fjallskog ML, Janson ET. Treatment of endocrine pancreatic tumors. Acta Oncol 2005; 44: 329–38
   PubMed Web of Science ®Google Scholar
• Lindahl P, Boström H, Karlsson L, Hellström M, Kalen M, Betsholtz C. Role of platelet-derived growth factors in angiogenesis and alveogenesis. Curr Top Pathol 1999; 93: 27–33
   PubMedGoogle Scholar
• Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendothelial sources of PDGFR-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003; 112: 1142–51
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and angiogenetic switch. Nat Rev Cancer 2003; 3: 401–10
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287–95
   PubMed Web of Science ®Google Scholar
• Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is angiogenetic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939–52
   PubMed Web of Science ®Google Scholar